A Phase I Open-label, Multi-dose, Dose Escalation and Dose Expansion Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
This study tests a new experimental medication called PLB1004 for people with a common type of lung cancer. Researchers want to find the safest and most effective dose to help target and fight cancer cells.
You may be able to join if you are an adult with a confirmed EGFR gene mutation and have finished recovering from previous cancer treatments or major surgeries. There are some health and treatment history rules, such as not having recent radiation, to keep you safe.
You will receive the experimental medication PLB1004 in a careful step-by-step process to monitor safety and find the right dose. Doctors and research staff will closely follow your health throughout the study.
This study is currently recruiting participants and takes place at medical centers in Sacramento, California; Louisville, Kentucky; and Omaha, Nebraska.
- 1Testing a new experimental medicine named PLB1004
- 2Open to adults with specific lung cancer gene mutations
- 3Currently recruiting at multiple locations in the United States
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.